National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

imexon
A 2-cyanoaziridine derivative with antitumor activity in multiple myeloma. Although its mechanism of action is not clearly known, imexon may induce apoptosis via a pathway involving cleaved caspase-3, caspase-9, and/or caspase-8. Other cytotoxic mechanisms of action of this agent may involve thiol depletion, generation of reactive oxygen species (ROS), and decreases in the mitochondrial membrane potential. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

US brand name:Amplimexon
Chemical structure name:4-imino-1,3-diazabicyclo[3,1,0]-hexan-2-one



Previous:IL-2/Lptn gene-modified allogeneic neuroblastoma tumor cell vaccine, iloprost, Ilotycin, Imagent, imatinib mesylate
Next:imidazole mustard, imipenem, imiquimod, ImmTher, Immucell WGP

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov